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Abstract
Developing a drug therapy that addresses the root cause of cystic fibrosis (CF) by increasing
CFTR protein levels has long been a research challenge. After genetic therapy failed because a
suitable delivery system could not be found, researchers began searching for small organic
molecules that could act as chaperones for CFTR. These molecules, known as modulators,
allowed CFTR to be assembled correctly and function similarly to wild type CFTR. Since 2012,
four modulator drugs have been developed, tested, and approved by the FDA. In October 2019,
Trikafta was approved as the first triple-combination modulator drug and has completely
revolutionized CF therapy. This paper details the research challenges, successes, and failures that
led to the development of modulator therapies.
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Modulator Therapy for Cystic Fibrosis: An Exploration of Current Research
Cystic Fibrosis Introduction
Cystic fibrosis (CF) is a genetic autosomal disease caused by a mutation in a key protein.
CF is the most common deadly genetic mutation in Caucasians and impacts 70,000 people
worldwide, who have a predicted median survival of 44.4 years old (up from 32.8 years old in
2003) (Bompadre, Li, & Hwang, 2008; CFF, 2019). CF is caused by a monogenic autosomal
recessive mutation that prohibits the cystic fibrosis transmembrane conductance regulator
(CFTR) protein from functioning normally. CFTR is essential for maintaining homeostasis in the
body by facilitating water movement through secretion of chloride, bicarbonate, and other
anions. The CFTR gene was cloned in 1989 which led to rapid increases in knowledge of
pathophysiology caused by mutant CFTR. Since then, CF research has focused on understanding
the role of CFTR in the body and developing treatments such as genetic therapy and modulators
which can reestablish CFTR function to the body.
CF affects many different organs in the body including the lungs, kidneys,
gastrointestinal and reproductive tracts, liver, and pancreas (Griesenbach, Pytel, & Alton, 2015).
Common symptoms of CF include salty-tasting skin, persistent sputum-producing coughing,
frequent lung infections, and greasy, bulky stools (CFF, 2019). Most recent data from the Cystic
Fibrosis Foundation 2018 Patient Registry list the median age at death to be 30.8 years for
individuals with CF with a median predicted survival age of 44.4 years for those born between
2014-2018 (CFF, 2019). While CF affects the whole body, more than 90% of fatalities are due to
lung disease; therefore, this paper will focus primarily on the lungs and treatments to help
improve lung function (Burney & Davies, 2012).
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This paper briefly explains how CF effects the body as well as several important CF
mutations to give a background into the research behind modulators. This background gives
insight into the research advancements and challenges of modulator research. In addition, this
paper lists all phase 2 and 3 placebo-controlled clinical trials that tested modulators. By
compiling details from all clinical trials on numerous different drugs, one can see trends in
clinical results and clearly see the successes and failures of various modulators.
CFTR’s impact on the body: a story of inflammation and mucus
A mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein
makes it impossible for the cell to maintain homeostasis. The CFTR gene codes for an ATPbinding cassette (ABC) transporter which creates a channel for chloride, bicarbonate, and other
anions to flow along their respective concentration gradients (Callebaut, Chong, & Forman-Kay,
2018). The CFTR protein is made of five domains: two membrane spanning domains (MSD1
and MSD2) each of which are composed of six transmembrane segments, two nucleotide binding
domains (NBD1 and NBD2,) and a regulatory domain (R) (Figure 1) (Farinha & Canato, 2017).
The two nucleotide binding domains dimerize in a head-to-tail configuration which requires two
ATP to open the channel (Y. Wang, Wrennall, Cai, Li, & Sheppard, 2014). In addition, the R
region contains a number of protein kinase A phosphorylation sites that react to an increase in
cAMP levels. The phosphorylation causes the R-region to stop sterically interfering with NBD
dimerization (Meng, Clews, Kargas, Wang, & Ford, 2017). In order to open the channel, the R
region must be properly phosphorylated by cAMP and one ATP must have bound to each of the
two nucleotide binding domains. In other words, the opening of the CFTR channel is not a
simple switch but instead responds to a variety of signals and requires at least two activating
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factors to open. This level of complexity means that a small mutation in the DNA can render the
entire protein nonfunctional (Meng et al., 2017).

Figure 1. Cartoon map of CFTR showing five domains and signaling molecules. CFTR is made
up of two membrane spanning domains (MSD), two nucleotide binding domains (NBD), and a
regulatory region (R) (Farinha & Canato, 2017). In order to open, the R doming must be
phosphorylated (P) and two ATP must have bound to the NBDs allowing them to dimerize
(Meng et al., 2017; Y. Wang et al., 2014). Once open, CFTR acts as channel for chloride and
other small ions. Figure adapted from (Fajac & Wainwright, 2017).
A normal CFTR protein functions to maintain water balance across the cell membrane.
When properly triggered by cAMP and ATP, the channel opens and allows chloride and
bicarbonate to flow along their concentration gradient, which for most situations, means that
these ions flow out of the cell. CFTR is the main channel for Cl- exit, which in turn triggers Na+
secretion to balance ion charges (Saint-Criq & Gray, 2017). The additional salt ions outside the
cell membrane draws water outside the cell through aquaporins. This water rehydrates airway
surface liquid (ASL) which is essential to the function of the mucociliarly escalator and to
preventing buildup of fluid and pathogens in the lungs. In addition, CFTR controls other Cl- and
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Na+ channels including the epithelial sodium channel (ENaC) (Collawn & Matalon, 2014).
CFTR functions as the master control to secrete salt and water from the cell, and without CFTR
the cell becomes very ineffective at secreting water (Collawn & Matalon, 2014).
CFTR is primarily expressed on exocrine tissues, where one of the main functions of the
tissue is to secrete water. The height of ASL is directly determined by the number of Na+ and Clions in the extracellular fluid (Boucher, 2003). In normal lungs, ASL is a low viscosity fluid
composed primarily of mucin fiber and a small amount of actin, DNA, and other
macromolecules (Ong, Mei, Cao, Lee, & Chung, 2019). Without CFTR, Cl- cannot be secreted
into the extracellular fluid, which results in low levels of osmotic pressure drawing water out of
the cell, eventually causing the ASL to lose height and volume while at the same time becoming
more viscous. Equally important is the fact that without CFTR, ENaC is not properly regulated
which results in constant Na+ absorption (Saint-Criq & Gray, 2017). By facilitating absorption of
salt, ENaC and CFTR work together to control the viscosity and height ASL. Because CF
patients lack CFTR, they cannot counteract ENaC, which results in hyperabsorption of sodium,
further dehydrating ASL.
Tall, low viscosity ASL is required for proper mucociliary clearance in the lungs
(Somayaji, Ramos, Kapnadak, Aitken, & Goss, 2017). In CF patients, the ASL has high viscosity
and cannot be easily cleared from the lungs. When the lungs lack effective muco-ciliary
clearance, thickened mucus can accumulate in distal airways and cause blockage of airways in
the form of mucus adhesions, mucus plaques, and plugs (Randell, Boucher, & University of
North Carolina Virtual Lung, 2006). If mucus is not cleared from the lungs, it creates barriers to
immune system function and provides a perfect place for bacteria to grow (Randell et al., 2006).
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Bacteria thrive in thick mucus. From eating mucinoses, to forming biofilms, which
prevent immune cells from killing bacteria, the thick mucus in CF lungs is hospitable to bacteria
(Randell et al., 2006). Furthermore, the thickened ASL restricts bacterial motility leading to high
local bacterial colony densities while simultaneously inhibiting neutrophil and macrophage
migration (Matsui et al., 2005). The protein defect in CF results in lungs primed for large scale
bacterial infection.
In addition, inflammation is increased by lack of HCO3- transport through CFTR. Beyond
forming a Cl- channel, CFTR can also transport other small anions including HCO3-. In the lungs,
HCO3- is responsible for reducing pH of ASL. Acidic ASL not only inhibits antimicrobial
peptides, proteins, and lipids which are inactivated at acidic pH, it also increases inflammation of
the lung tissue (Stoltz, Meyerholz, & Welsh, 2015). Furthermore, CF macrophages and
neutrophils tend to be hyperinflammatory with exaggerated responses to bacterial infection
leading to recruitment of more neutrophils (Conese, 2011; Ralhan et al., 2016). The increased
level of neutrophils and increased secretion of proinflammatory cytokines from macrophages
create a death spiral of chronic infection (Bruscia et al., 2009). Moreover, studies have found that
airway phlegm in CF patients contains little intact mucin but rather consists of bacteria,
inflammatory cells, and F-actin; the ASL is more characteristic of pus rather than mucus (Flume
& Van Devanter, 2012).
Chronic lung infections and high levels of inflammation lead to irreversible lung damage
by scarring lung tissue. This scarring can lead to advanced lung disease that slowly becomes
respiratory failure. Eventually these repeat infections and high inflammation levels destroy the
lungs completely, and a double lung transplant is required.
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Without functional CFTR, a person is not able to survive, and even with modern medical
advances, CF patients have a much shorter life expectancy because CFTR is so vital to maintain
homeostasis. Death is usually caused by lung failure, which is a result of repeated lung infections
and high levels of inflammation. The lack of one protein completely destroys homeostasis and
prevents the body from adequately regulating osmotic pressure, clearing the lungs, or effectively
fighting bacteria.
CFTR Mutations
Because CF is a recessive, monogenic disease, one common way to classify CF patients
is by their mutations. Of the 281 identified disease causing mutations, the F508del mutation is
homologous in 70% of CF patients, and the G551D mutation is present in another 4% (Fajac &
Wainwright, 2017; Hart & Harrison, 2017). The mutations fall into six broad categories. Class I
mutations are caused by a premature stop codon which results in no full-length CFTR. Caused
by a processing defect, class II mutations result in nonfunctional CFTR that are usually
destroyed in the endoplasmic reticulum (ER). Class III are gating mutations caused by a
regulation defect where the channel will not open when signaled by cAMP and ATP. Class IV is
a result of decreased conductance; class V represents reduced synthesis, and class VI results in
increased turnover in membrane (Bosch & De Boeck, 2016). Also known as residual function
(RF) or minimal function (MF), classes IV-VI cause less severe CF as some proteins are usually
able to survive and maintain some level of homeostasis. The F508del mutation, a class II
mutation, and G551D, a class III mutation, are particularly significant because modulator
treatments are currently available for both of them.
The F508del mutation is caused by a deletion of a phenylalanine (F) at codon 508. This
mutation is the most common mutation seen in CF patients, and it has been estimated that 95%
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of patients possess at least one allele with this mutation (Meng et al., 2017). Codon 508 alters the
secondary structure of the protein, and without this phenylalanine, the connection between
MSD2 and NBD1 is very unstable (Bartoszewski et al., 2010; Meng et al., 2017). Endoplasmic
reticulum (ER) quality control mechanisms such as the 26S proteasome register this instability
and destroy the faulty protein (Carlile et al., 2018; Clancy, 2018). In addition, even if F508del
reaches the plasma membrane, it also exhibits gating defects and protein instability in the plasma
membrane (Clancy, 2018). Because this mutation results in very low levels of CFTR proteins to
reach the cell membrane, it is considered a class II mutation.
The second mutation of note is the G551D mutation, which is caused by an aspartic acid
(D) substitution for glycine (G) at codon 551 located within NBD1 (Derand, Bulteau-Pignoux,
& Becq, 2003). As a result, the NBD1 section is unable to bind and hydrolyze ATP. The protein
folds correctly, goes to the plasma membrane, and the R region is correctly phosphorylated, but
the NBD1 section is unable to dimerize with NBD2 because it cannot hydrolyze ATP
(Bompadre et al., 2008). Therefore, the protein rarely opens because it is unable to bind to the
energy source it needs to open the gate, making this mutation a class III mutation. While the
G551D mutation is not as common as F508del because the protein makes it all the way to the
surface and there is only one section that is malfunctioning, many researchers believed that
correcting this mutation should be an easier fix.
CF Treatment Overview
There are two main drives with CF lung treatments. The first is downstream treatments.
These strive to treat the symptoms of CF. The goal is to clear out sputum, also known as mucus,
from the lungs via airway clearance techniques, to control and prevent bacterial infections via
antibiotics, and to reduce inflammation in the lungs. Together these treatments can improve lung
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function, but they are not without their drawbacks. Airway clearance techniques can take hours
every day, certain bacteria are antibiotic resistant, and only so much inflammation can be
reduced. In addition, as CF is a chronic, progressive disease, these treatments are not able to keep
up with the progression of the disease. For many years, these downstream therapies were the
only option to help those with CF, and each new advancement and discovery added years to CF
patients’ lives. But with modern research, new therapies are now available that can address the
root cause of CF: the lack of CFTR.
The second drive for CF treatment is to establish CFTR protein function to the lungs and
other organs and thereby return the body to normal homeostasis. The two methods that have been
proposed to accomplish this goal is genetic therapy and modulators. By delivering wildtype
DNA or RNA to cells, genetic therapy allows cells to make wtCFTR using normal cell
processes. However, genetic therapy has faced some serious research development challenges in
identifying a suitable vector. Since 1989 there have been over 25 human clinical trials testing
genetic therapy using various viral and non-viral vectors, yet none of these trials have been
successful (Alton et al., 2016; Griesenbach & Alton, 2011; Griesenbach et al., 2015).
Researchers have been unable to design a vector that can bypass the body’s defenses and
successfully deliver genetic material. While this is a testament to the amazing design of the
human body’s immune system, it means that genetic therapy has not proved an effective
treatment for CF. After the failures of genetic therapy, researchers moved onto studying
modulators, which fix the mutated CFTR by acting as readthrough agents or binding to the
mutated CFTR to correct structural or gating insufficiencies. These small organic molecules do
not require a vector for delivery, and thus did not face the same research challenges. In fact, four
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different modulators have been developed which turn mutated CFTR into functioning CFTR
allowing CF cells to maintain homeostasis.
Modulator Therapy Introduction
Modulators help to increase or restore function of mutated CFTR by directly interacting
with mutated CFTR and are thereby inherently mutation specific. Depending on the mechanism
of action, modulators are put into three different categories: potentiators, correctors, and
amplifiers. Potentiators keep CFTR channels open once they are in the plasma membrane
(Guimbellot, Sharma, & Rowe, 2017). Correctors act as chaperones to prevent misfolding of
CFTR in the ER and to transport CFTR to the plasma membrane (Guimbellot et al., 2017).
Amplifiers increase the amount of CFTR protein the cell produces (Giuliano et al., 2018). There
are three ways to improve activity of CFTR: by increasing the number of CFTR channels on the
plasma membrane, increasing the time that the channels are open, or increasing the size or
conductance of the channel (Clancy, 2018). Modulators can improve CFTR function in the cell
by increasing any one of these variables.
Currently there are four CF modulator therapies available to patients: Ivacaftor,
Lumacaftor/Ivacaftor, Tezacaftor/Ivacaftor, and Elexacaftor/Tezacaftor/Ivacaftor. Ivacaftor was
the first drug approved by FDA on January 31, 2012 for treatment of CF patients with the
G551D mutation (FDA, 2012). Ivacaftor is a potentiator which increases the time a CFTR
channel is open and works for a large variety of mutations. Lumacaftor, Tezacaftor, and
Elexacaftor are all correctors that were primarily designed to correct mutated F508del CFTR.
When combined with Ivacaftor, these drugs form a combination therapy, where the corrector is
responsible for the folding of CFTR, which allows it to be trafficked to the plasma membrane
while Ivacaftor increases the possibility that the channel is open. The most recent addition to
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these drug therapies is Trikafta (Elexacaftor/Tezacaftor/Ivacaftor) which was approved by the
FDA on October 21, 2019 and is the first second-generation, triple-combination modulator
therapy (FDA, 2019).
The tables in the next few sections list all phase 2 or 3 placebo-controlled clinical trials
using modulators published up to December 31, 2019. Journal articles were found primarily via
pubmed, proquest, and google scholar searches of individual drug names as well as searches on
clinicaltrials.gov, FDA.gov, and searches of pharmaceutical websites. In order to be included, the
trial must be placebo controlled and report results either in ppFEV1 change or sweat chloride
change. FEV1 is one of several tests that measures pulmonary function. FEV1 measures the
forced expiratory volume at the end of the first second of measurement during a large exhale
from the patient. ppFEV1 is the percent predicted FEV1, which compares a patient’s results to the
predicted normal values for their age, sex, height, weight, and ethnicity; the result is expressed as
a percentage of the normal value. For CF patients, ppFEV1 is one of the most common measures
of lung function and how well their lungs are working. Improvement in ppFEV1 is usually the
main endpoint for clinical trials of modulator therapies because it shows quantitatively that the
drug is helping improve lung function. Most clinical trials required an initial ppFEV1 between
40-90% to participate as a ppFEV1 lower than that signifies late-stage pulmonary disease and the
potential need for a lung transplant (Pettit & Fellner, 2014; Ramos et al., 2019).
The second commonly used endpoint for clinical trials is change in sweat chloride. The
sweat test is used to diagnose CF and is a relatively simple test where sweat is stimulated using
pilocarpine iontophoresis, collected, and then the chloride concentration is measured within the
sweat (LeGrys et al., 2007). A result of <30 mmol/L is the normal result and indicates that CF is
unlikely, 30-59 mmol/L requires more testing, and >60 mmol/L indicates CF (Farrell et al.,
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2017). High chloride sweat content is present in CF patients because the body is unable to
reabsorb chloride from the sweat (Quinton, 2007). A decrease in chloride content from the sweat
test would indicate that CFTR receptors are being expressed on the cell surface and functioning
properly.
Note, the tables below list the relative change in ppFEV1 and sweat chloride. That is to
say the treatment result is compared to the placebo result and the relative change is reported to
most clearly show how the treatment compared to the placebo. These tables allow easy
comparison of different modulator drugs and show the process of developing drugs that provide
high levels of clinical benefit.
Ivacaftor: The First Modulator
Currently four modulator regimens have been approved by the FDA. The first of these
was Ivacaftor, also known as Kalydeco or VX-770, which was originally approved for patients
with at least one G551D allele. Since its original FDA approval, Ivacaftor has been approved for
33 more mutations including most of the gating mutations (Eisenman, 2017). Developed by
Vertex Pharmaceuticals, Ivacaftor is a small organic molecule that was initially found using high
throughput screening assays (Van Goor et al., 2009). Using human bronchial epithelial (HBE)
cells from CF patients with the G551D mutation, F508del mutation, and control non-CF cells,
Ivacaftor’s effect was tested. The study showed Ivacaftor increased CFTR channel open
probability and increased chloride secretion to approximately 50% of normal chloride secretion
in wtCFTR cells (Van Goor et al., 2009). In addition, Ivacaftor prevented dehydration of ASL
and increased cilia beating (Van Goor et al., 2009). After this very promising test, Ivacaftor
moved to human clinical trials (Table 1).
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Table 1: Ivacaftor Clinical Trials
Reference
NAME Details

Participants

N

Treatment

(Accurso et
al., 2010)

- G551D ≥1 allele
- Age ≥ 18

20

(Accurso et
al., 2010)

- G551D ≥1 allele
- Age ≥ 18

IVA 25, 75, or 150 mg
BID
2 x 14 day periods

Percent Change
in ppFEV1
25 mg: 4.2%
75 mg: 9.3%
150 mg: 9.8%

Sweat chloride change
(mmol/L)
25 mg: -37.3
75 mg: -44.8
150 mg: -46.3

19

IVA 150 or 250 mg BID
28 days

150 mg: 1.4%
250 mg: -3.1%

150 mg: -64.5
250 mg: -43.0

(Ramsey et
al., 2011)

STRIVE

- G551D ≥1 allele
- Age ≥ 12

161

150 mg IVA BID
48 wks

10.5%

-48.1

(Flume et al.,
2012)

DISCOVER

- F508del homo
- Age ≥ 12

140

150 mg IVA BID
16 wks

1.9%

- 2.9

(J. C. Davies
et al., 2013)

ENVISION

- G551D ≥1 allele
- Age 6-11

52

150 mg IVA BID
48 wks

10%

-54.3

(J. Davies et
al., 2013)

Crossover 2x2a

- G551D≥1 allele
- Age ≥ 6
- ppFEV1 ≥ 90%

21

IVA 150 mg BID
- 28 days IVA or PBO
- 28 days WO

8.67%

(De Boeck et
al., 2014)

KONNECTION,
Crossover 2x2a

- Non G551D gating
mutation ≥1 allele
- Age ≥ 6

39

IVA 150 mg BID
- 8 wks IVA or PBO
- 4-8 wks WO

10.68%

-49.17

(Moss et al.,
2015)

KONDUCT

- R117H ≥1 allele
- Age ≥ 6

69

150 mg IVA BID
24 wks

2.1%

-24.0

(Nick et al.,
2019)

N-of-1 study,
Crossover 2x2a

- 2 RF mutations
- Age ≥ 12

21

IVA 150 mg BID
2.3%
- 2 wks IVA and 2 wks
of PBO (order random)
- 4-8 wks WO
Note. All placebo controlled, phase 2 or phase 3 clinical trials testing ivacaftor by itself were found through a literature search and compiled.
Relative results comparing treatment and placebo are listed in the last two columns. homo = homozygous; IVA = ivacaftor; PBO = placebo; WO =
washout period; RF = residual function.
a
Crossover 2x2 means that participants received treatment (IVA or PBO) for first period, then took nothing during washout period, followed by
opposite treatment (PBO if they received IVA first time, or IVA if PBO was received first time) and a second washout period. This study design
allows testing of ivacaftor against placebo in a single individual.
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Table 1 demonstrates that Ivacaftor produces significant results both in ppFEV1 change
and sweat chloride change for individuals with at least one G551D allele. Ivacaftor works by
binding directly to the CFTR protein and causes spontaneous ATP-independent opening of the
channel (Eckford, Li, Ramjeesingh, & Bear, 2012; Jih & Hwang, 2013). When Ivacaftor is
bound, phosphorylation of the regulatory region of CFTR is required, but ATP is not required to
dimerize NBD1 and NBD2 domains. This corrects the G551D mutation, which does not respond
to ATP and thus rarely opens. Ivacaftor has little effect on homologous F508del because
Ivacaftor only increases the open probability of CFTR channels already in the plasma membrane
while F508del CFTR never reaches the plasma membrane (Flume et al., 2012). In addition, a
2019 study used a n-of-1 study method to test Ivacaftor’s effect on rare residual mutations (Nick
et al., 2019). N-of-1 studies use a crossover method of receiving placebo or treatment
successively to test results of treatment when only one participant can be found with the given
mutation. This is very helpful in research because it opens up possibilities of FDA approval of
modulators for those with very rare CF mutations. Because Ivacaftor also increases the
likelihood that a wtCFTR channel will be open, it has been approved for 33 different mutations
including, gating, residual function, splice, and conduction mutations (Eisenman, 2017). While
Ivacaftor may only cause clinical change in certain mutations that make up a small percentage of
total CF patients, Ivacaftor is the gold standard in modulator therapy for reliably providing large
amounts of clinical change (FDA, 2017).
Lumacaftor: Modulator Treatment for F508del Homozygous Mutation
The next modulator to be developed was Lumacaftor, also known as VX-809, which was
also developed by Vertex Pharmaceuticals. Falling into the category of correctors, Lumacaftor
was designed to prevent misfolding of F508del CFTR. The F508del mutation is the most
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common mutation and is homologous in about 70% of CF patients (Fajac & Wainwright, 2017).
Lumacaftor works cotranslationally by altering the protein conformation of MSD1, which in turn
allows a more stable connection between MSD1 and NBD1, thus partially correcting the F508del
mutation (Ren et al., 2013). An initial clinical trial was completed using just Lumacaftor for
homologous F508del CF patients, but the results showed that Lumacaftor by itself had no effect
on ppFEV1 or sweat chloride (Table 2) (Clancy et al., 2012). This is due to the fact that F508del
CFTR exhibits not only folding defects but also gating defects (Clancy, 2018). However, when
Lumacaftor was combined with Ivacaftor to create a dual modulator treatment, the combined
therapy established some CFTR function. Lumacaftor would facilitate correct folding of the
CFTR and Ivacaftor would increase the time it was open.
Lumacaftor/Ivacaftor, also known as Orkambi, has some clinical benefit for F508del
homozygous patients but no effect for heterozygous F508del patients (Boyle et al., 2014). In
addition, researchers found that a large daily dose of Lumacaftor was more effective than
splitting the dose into two daily doses (Ratjen et al., 2017; S. M. Rowe, McColley, et al., 2017).
Compared to Ivacaftor’s effect on G551D mutation, Lumacaftor/Ivacaftor results in a much more
modest improvement in lung function. The change is more consistent with therapies that treat
downstream symptoms of CF (Deeks, 2016). Yet, Lumacaftor/Ivacaftor does cause a significant
reduction in the rate of FEV1 decline thereby allowing a stabilization in ppFEV1 (Talamo
Guevara & McColley, 2017). Because of this and the modest improvement in lung function,
Lumacaftor/Ivacaftor was approved by the FDA in 2015 (FDA, 2015).
Tezacaftor: a Lumacaftor Replacement
Tezacaftor or VX-661 has a similar structure to Lumacaftor and was developed as a
replacement for Lumacaftor. Tezacaftor is a broader-acting CFTR corrector that enables cellular
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Table 2: Lumacaftor Clinical Trials
Reference
NAME
Participants
Details
(Clancy et
- F508del homo
al., 2012)
- Age≥18

N

Treatment

89

LUM 25 mg, 50 mg, 100 mg, or
200 mg QD
28 days

18

Percent Change in
ppFEV1
25 mg: -2.46%
50 mg: -2.15%
100 mg: .32%
200 mg: .47%

Sweat chloride change
(mmol/L)
25 mg: 0.1
50 mg: -4.61
100 mg: -6.13
200 mg: -8.21

(Boyle et
al., 2014)

Cohort 1

- F508del homo
- Age ≥18

62

- LUM 200 mg QD for 21 days
- IVA 150 mg or 250 mg BID
was added for last 7 days

150 mg: 2.7%
250 mg: .2%

150 mg: -5
250 mg: -10.9

(Boyle et
al., 2014)

Cohort 2

- F508del homo
and F508del het
- Age ≥18

109

- LUM 200 mg, 400 mg, or 600
mg QD for 56 days
- IVA 250 mg BID added in for
last 28 days

200 mg: 3.8%
400 mg: 2.7%
600 mg (homo): 5.6%
600 mg (het): .3%

200 mg: -5.12
400 mg: -9.8
600 mg (homo): -9.6
600 mg (het): -6.0

(Boyle et
al., 2014)

Cohort 3

- F508del homo
- Age ≥18

15

- LUM 400 mg BID for 56 days
- IVA 250 mg BID added in for
last 28 days

4.2%

-11.1

(Wainwright
et al., 2015)

TRAFFIC
TRANSPORT

- F508del homo
- Age≥12

1108

- LUM 400 mg QD + IVA 250
mg BID
- LUM 600 mg BID + IVA 250
mg BID
24 wks

400 mg: 4.8%
600 mg: 5.6%

(Ratjen et
al., 2017)

- F508del homo
- Age 6-11

204

LUM 200 mg BID + IVA 250
mg BID
24 wks

2.4%

(Rowe et al.,
2017b)

- F508del het
- Age ≥18

126

-20.8

LUM 400 mg BID + IVA 250
.6%
-11
mg BID
56 days
Note. All placebo controlled, phase 2 or phase 3 clinical trials testing lumacaftor by itself or in combination with ivacaftor were found through a
literature search and compiled. Relative results over the entire study comparing treatment and placebo are listed in the last two columns. homo =
homozygous; het = heterozygous; LUM = lumacaftor; IVA = ivacaftor.
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production and facilitates trafficking of multiple mutant forms of CFTR including F508del (S.
M. Rowe, Daines, et al., 2017). Furthermore, because Tezacaftor does not induce CYP3A4
enzymes, there are less drug-drug interactions than Lumacaftor (Donaldson et al., 2018). This
means Tezacaftor is safer and improves lung function in more mutations than Lumacaftor.
Clinical trials showed that Tezacaftor/Ivacaftor treatment resulted in similar levels of change in
ppFEV1 and sweat chloride as Lumacaftor/Ivacaftor treatment (Table 3).
Based on these clinical trials, symdeko therapy was created which uses Tezacaftor/
Ivacaftor, which was approved by the FDA in February 2018 for patients with one allele of
F508del and an Ivacaftor-responsive residual function allele (FDA, 2018; S. M. Rowe, Daines, et
al., 2017). This meant that modulator therapy was now available for more people with CF. For
homologous F508del patients, there is similar clinical benefits from both Lumacaftor/Ivacaftor
and Tezacaftor/Ivacaftor, but Tezacaftor/Ivacaftor is responsible for less adverse side effects
(Kirby, 2018).
Trikafta: The Challenge of Finding a Triple-Combination Modulator
The next step in modulator development was to create triple-combination modulators also
known as second generation modulators. It was theorized that adding a second corrector to the
Tezacaftor/Ivacaftor combination with a complementary mechanism of action would better
restore CFTR function (Heijerman et al., 2019). In addition, the goal was to develop a modulator
that would provide modulator therapy to the 30% of CF patients who are heterozygous for
F508del and a minimal function mutation (Davies et al., 2018). Minimal-function mutations
include nonsense, insertion/deletion, splicing, and several severe protein misfolding mutations
(Davies et al., 2018). The goal was to develop a modulator regimen that could correct CFTR
function from the one F508del allele regardless of what the second allele is. Vertex
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Table 3: Tezacaftor Clinical Trials
NAME
Participants
N
Reference
(Donaldson - F508del
131
et al.,
homo
2018)
- Age ≥ 18

20

Treatment

Percent Change in ppFEV1

TEZ monotherapy:
TEZ 10, 30, 100, or 150 mg QD
Combination therapy:
TEZ 10, 30, 100, or 150 mg QD + IVA
150 mg BID
28 days

TEZ monotherapy:
- 10 mg = 3.63%
- 30 mg = 1.77%
- 100 mg = 1.74%
- 150 mg = 2.68%
Combination therapy:
- 10 mg = 1.44%
- 30 mg = 3.04%
- 100 mg = 3.89%
- 150 mg = 3.75%

Sweat chloride change
(mmol/L)
TEZ monotherapy:
- 10 mg = 4.78
- 30 mg = -3.9
- 100 mg = -19.57
- 150 mg = -9.6
Combination therapy:
- 10 mg = -4.2
- 30 mg = -5.14
- 100 mg = -5.18
150 mg = -1.77

(Donaldson - F508del
et al.,
homo
2018)
- Age ≥ 18

67

- TEZ 100 mg QD + IVA 150 mg BID
- TEZ 100 mg QD + IVA 50 mg BID
- LUM 50 mg BID + IVA 150 mg BID
28 days

TEZ 100 + IVA 150 = 2.19%
TEZ 50 + IVA 150 = .84%
LUM 100 + IVA 50 = -.53%

TEZ 100 + IVA 150 = -4.13
TEZ 50 + IVA 150 = -6.7
LUM 100 + IVA 50 = -4.88

(Donaldson - F508del/
et al.,
G551D
2018)
- Age ≥ 12

18

TEZ 100 mg QD + IVA 150 mg BID
28 days

3.2%

-17.2

EVOLVE
(TaylorCousar et
al., 2017)
EXPAND
(Rowe et
al., 2017a)

510

TEZ 100 mg QD + 150 mg IVA BID
24 wks

6.8%

- F508del
homo
- Age≥12

Crossover 3x2a
TEZ + IVA = 6.8%
TEZ + IVA = -9.5
- TEZ 100 mg QD + IVA 150 mg BID
IVA = 4.7%
IVA = -4.5
- IVA 150 mg BID
8 wks treatment
8 wks WO
Note. All placebo controlled, phase 2 or phase 3 clinical trials testing tezacaftor by itself or in combination with ivacaftor were found through a
literature search and compiled. Relative results comparing treatment and placebo are listed in the last two columns. Homo = homozygous; TEZ =
tezacaftor; LUM = lumacaftor; IVA = ivacaftor; WO = washout; RF = residual function.
a
3 sets of a different treatment or placebo followed by washout.
- F508del +
RF
- Age≥12

248
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Pharmaceuticals initially identified two very similar modulators that could be added to the
Tezacaftor/Ivacaftor combination. To test which drug was better, Vertex completed separate
phase 2 and phase 3 studies on VX-659 and VX-445 and compared the results (Table 4).
VX-659 and VX-445 are correctors that decrease misfolding of CFTR and promotes
trafficking of CFTR from ER to plasma membrane (Davies et al., 2018). More importantly, they
have an additive effect to Tezacaftor (Davies et al., 2018; Keating et al., 2018). Clinical trials
showed that both VX-659 and VX-445 triple combination therapy showed drastic lung
improvement in both homozygous and heterozygous patients. This level of benefit is similar to
Ivacaftor’s benefit for the G511D mutation and has the ability to drastically improve a patient’s
quality of life.
After running parallel phase 3 studies of VX-659 and VX-445, Vertex decided that VX445, also known as Elexacaftor, was the more effective drug. Both studies included a 24 week
test for patients with one F508del mutation and one MF mutation along with a 4 week test for
homozygous patients. Both programs met their primary and secondary endpoints, and both of the
triple combinations were generally well tolerated with a low amount of adverse effects (Vertex,
2019b). Based on all the data, Vertex submitted Elexacaftor in combination with Tezacaftor/
Ivacaftor for FDA approval. On October 21, 2019, Trikafta (Elexacaftor/Ivacaftor/ Tezacaftor)
was approved by the FDA for patients with at least one F508del mutation (Arnold, 2019). This
drug opens up life-saving modulator treatment to over 90% of the CF population. It is available
to patients who previously were ineligible for modulator therapy and greatly improves lung
efficiency over previous modulator drugs. For the 27,000 people in the United States that this
drug is approved for, Trikafta means additional years of life, greatly improved quality of life, less
hours spent in airway clearance, less fear to pulmonary exacerbations, and a healthier body.
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Table 4: Triple Combination Drug Trials
Reference
Participants
N

Treatment

22

Percent Change in
ppFEV1
80 mg = 9.8%
240 mg = 11.6%
400 mg = 12.9%

Sweat chloride
change (mmol/L)
80 mg = -48.6
240 mg = -46.7
400 mg = -54.3

(Davies et
al., 2018)

- F508del + MF
- Age ≥ 18

63

VX-659 80, 240, or 400 mg QD + TEZ 100 mg QD + IVA 150 mg
BID
4 wks

(Davies et
al., 2018)

- F508del homo
- Age ≥ 18

29

VX-659 400 mg QD+ TEZ 100 mg QD + IVA 150 mg BID (placebo
group received TEZ +IVA)
4 wks

9.7%

-45.2

(Davies et
al., 2018)

- F508del + MF
- Age ≥ 18

25

VX-659 400 mg QD + TEZ 100 mg QD + VX-561 200 mg QD
4 wks

17.2%

-36.8

(Vertex,
2019a)a

385

VX-659 400 mg + TEZ 100 mg QD + IVA 150 mg BID
24 wks

14% at week 4

(Vertex,
2019a)a

-

111

VX-659 400 mg + TEZ 100 mg QD + IVA 150 mg BID (placebo
group received TEZ +IVA)
4 wks

10%

(Keating et
al., 2018)

- F508del + MF
- Age ≥ 18

95

VX-445 50, 100, or 200 mg QD + TEZ 100 mg QD + IVA 150 mg
BID
4 wks

50 mg =11.1%
100 mg = 7.9%
200 mg = 13.8%

50 mg = -36
100 mg = -31
200 mg = -36.9

(Keating et
al., 2018)

- F508del homo
- Age ≥ 18

28

VX-445 200 mg QD+ TEZ 100 mg QD + IVA 150 mg BID (placebo
group received TEZ +IVA)
4 wks

10.6%

-40.4

(Keating et
al., 2018)

- F508del + MF
- Age ≥ 18

29

VX-445 200 mg QD + TEZ 100 mg QD + VX-561 200 mg QD
4 wks

10.5%

-34.6

(Middleton
et al.,
2019)

- F508del + MF
- Age ≥ 12

403

VX-445 200 mg + TEZ 100 mg QD + IVA 150 mg BID
24 wks

14.3%

-41.8

F508del + MF
Age ≥ 12
F508del homo
Age ≥ 12

(Heijerman - F508del homo
107
VX-445 200 mg QD+ TEZ 100 mg QD + IVA 150 mg BID (placebo
10%
-45.1
et al.,
group received TEZ +IVA)
- Age ≥ 12
2019)
4 wks
Note. All placebo controlled, phase 2 or phase 3 clinical trials testing VX-445 or VX-659 published before Dec 2019 were found through a literature search and
compiled. Relative results comparing treatment and placebo are listed in the last two columns. MF = minimal function; homo = homozygous TEZ = tezacaftor;
IVA = ivacaftor.
a
Vertex pharmaceuticals did not actually publish a journal article phase 3 testing of VX-659 because it was never submitted for FDA approval or researched
further. These results are from a press release from Vertex Pharmaceuticals on the phase 3 trial results. They are included to allow easy comparison between VX659 and VX-445.
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While it is important to note that Trikafta is not a cure for CF, and if at any time a patient is
unable to continue the therapy, they will shortly return to the same baseline before modulator
treatment, Trikafta is a major research accomplishment in developing a therapy that establishes
CFTR function in the vast majority of CF patients (Trimble & Donaldson, 2018).
Failed Modulator Developments
However not every clinical trial is a success nor does every drug tested make it to market.
During the research process there are numerous drugs that are developed and tested, but at some
point, they fail, and research on that drug is stopped. Oftentimes in vitro studies or even phase 1
studies show very promising results, but during phase 2 or phase 3, clinical benefit is not
achieved, and the drug is abandoned. When this happens, sometimes journal articles are written
and explain the failure and why it happened, but other times the failure is not recorded, and the
pharmaceutical company simply switches to another project. Currently there are two failed drugs
that made it to phase 2 or 3 in placebo-controlled trials that published at least an abstract.
In 2014 PTC Therapeutics tested Ataluren in a phase 3 clinical trial (Table 5) (Kerem et
al., 2014). Ataluren is an amplifier which was designed to prevent nonsense mutations (Class I)
from happening (Guimbellot et al., 2017). While Ataluren performed well in early clinical trials,
results from phase 3 clinical trials were not statistically significant. Because Ataluren has a
similar structure to tobramycin (a commonly used antibiotic), it was hypothesized that chronic
tobramycin use inhibited Ataluren. However, even excluding patients who used tobramycin, a
retrospective analysis found that Ataluren still did not cause clinically significant change (Kerem
et al., 2014).
Another drug that was developed then disregarded was QBW251, a potentiator, which
was developed by Novartis Institutes. While the phase 2 trial showed somewhat positive results
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for patients with gating or residual function mutations, it seems that QBW251 has since been
abandoned as a CF treatment (Table 5) (Kazani, 2016). Instead QBW251 was tested in 2018 in
people with COPD and may have applications in other respiratory diseases (S. Rowe et al.,
2018).
Analyzing failures gives insight into the time, money, and risks that medical research
requires. Each of these failures as well as the hundreds of potential drugs that were abandoned
after phase 1 trials represent years of development, hundreds of recruited patients willing to try
an experimental drug, and millions of dollars. Yet without these failures, new lifesaving drugs
would not be developed. Failures are a reality of any development process, and in
pharmaceutical development, failures show the challenges of developing drugs that cause the
human body to drastically change the way it functions.
Current Modulatory Summary
From initial FDA approval of Ivacaftor in 2012, a large amount of research and
development has gone into modulator therapies. Because CFTR modulators are inherently
mutation specific, one of the major research drives is to expand currently approved drugs to new
mutations. This process was started in 2017 when the FDA approved Ivacaftor for 23 additional
mutations based solely on in vitro trials (FDA, 2017). This decision is very beneficial because
some mutations are so rare that there are simply not enough people to do a clinical trial, but the
access to modulator therapy can greatly improve and extend their lives. While n-of-1 studies help
to expand access to modulator treatments, the approval of additional mutation based solely on in
vitro trials means that lifesaving treatment is available to more people. Even with Ivacaftor being
approved for these additional mutations, modulator therapy was still only available for a small
amount of the CF population before the development of Lumacaftor.
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Table 5: Failed Drug Trials
Referen Participants
ce
(Kerem - Class 1
et al.,
mutation
2014)
- Age ≥ 6
- N=238
(Kazani,
2016)

- GM or RF ≥
1 allele
- N=26

(Kazani,
2016)

- F508del
homo
- N=14

Treatment
Ataluren (10 mg/kg at
breakfast, 10 mg/kg at
lunch, 20 mg/kg at
dinner)
48 wks
QBW251 150 or 450
mg BID
2 wks
QBW251 450 mg BID
2 wks

25

Percent Change in
ppFEV1
3%
5.7% (for patients not
using chronic inhaled
tobramycin)

Sweat chloride
change (mmol/L)

450 mg = 7.3%

150 mg = -16.9

No change

No change

Note. Placebo controlled, phase 2 or phase 3 clinical trials testing drugs that did not proceed further
published before Dec 2019 were found through a literature search and compiled. Relative results
comparing treatment and placebo are listed in the last two columns. GM = gating mutation; RF =

residual function; homo = homozygous.
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The second research drive was to combine modulators to develop new drugs to better
remedy the F508del mutation. Both Lumacaftor and Tezacaftor were unable to produce clinically
significant results by themselves, but when combined with Ivacaftor, these drugs were able to
restore some clinical function. The development of Lumacaftor/Ivacaftor meant that modulator
treatment was available to the 70% of CF patients homozygous for F508del (Fajac &
Wainwright, 2017). However, Lumacaftor/Ivacaftor only produced a modest improvement in
lung function (Table 2).
This led to the third research drive, which is the development of new drugs that are safer
and produce more clinical benefit. Tezacaftor was developed to try to solve this problem, and
because of its increased safety and fewer drug-related interactions, it has replaced Lumacaftor. In
addition, Tezacaftor/Ivacaftor treatment was not limited to people F508del homozygous
mutations but also produced benefit in some F508del heterozygous patients (Table 3).
The fourth research drive was to create a triple combination therapy. This was done by
adding a second corrector (Elexacaftor) to the Tezacaftor/Ivacaftor combination that amplified
Tezacaftor’s effect. By adding a third drug, the effect of the modulator treatment is multiplied as
more CFTR is folded correctly and is more stable which allows for transport from ER to the cell
surface. Furthermore, this second-generation modulator opened up treatment to all CF patients
with at least one F508del mutation, meaning that 90% of CF patients now have access to
modulator treatment. In the future this research drive will continue as new drugs are developed to
allow more CFTR to be produced until CFTR levels in CF patients resemble normal levels. Until
that goal has been accomplished, there is still much more research that can be done to develop
new modulators.
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Overall, modulator therapy is a growing field of CF treatment that has the possibility of
changing a CF diagnosis from a fatal life sentence to a tolerable disease. Modulators will never
be able to completely cure CF, but the hope is that they will restore enough CFTR function to
allow patients to live normal lives. Modulators are beginning to drastically change what life with
CF looks like. While hours of daily treatment, immune compromised states, pulmonary
exhibitions, and long hospital stays are still part of daily life for many CF patients, this does not
have to be the case. Modulators have the potential to restore CFTR function to normal non-CF
levels, but they still need more development and research to fully complete this goal. Modulators
are the route to fulfilling CF patients’ hope that one day there will be no need for lung
transplants, weeks of IV antibiotic treatment, or the fear of a mother that they will bury their
child because of this chronic disease. There is a hope that in years to come, Trikafta will be
looked back upon as the drug that started the progression of changing CF from a life sentence to
a livable disease.
Future Modulator Research
Even with the amazing accomplishment that Trikafta is, research is not done. Vertex
Pharmaceuticals and several other companies are working hard to create new, more effective,
and safer modulators. To begin with, Vertex Pharmaceuticals is testing a deuterated form of
Ivacaftor known as VX-561 (formerly known as CTP-565). Deuteration is the process of
replacing one or more hydrogen atoms with deuterium. This form of Ivacaftor is more stable in
vitro and would be taken once daily rather than the current form which is taken twice a day
(Harbeson et al., 2017). VX-561 was actually included in the two phase 2 clinical trials testing
VX-659 and VX-445 and showed promising results (Davies et al., 2018; Keating et al., 2018).
VX-561 is beginning its own phase 2 clinical trials and may replace Ivacaftor in the future.
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Vertex Pharmaceuticals is the only company to develop and receive approval for a
modulator therapy for CF, but they are not the only company developing modulator therapies
(Table 6) (Chaudary, 2018). A cooperation between AbbVie and Galapagos Cystic Fibrosis
Collaboration has led to the development of several novel modulators. To begin with, GLPG222
is a corrector that was found to be 25-fold more potent than Lumacaftor in cell line testing (X.
Wang et al., 2018). However, in human trials GLPG2222 unfortunately only produced minor
improvements (Bell et al., 2019). The second possibility is GLPG 2737, another corrector which
resembles Elexacaftor and VX-659. GLPG2737 demonstrated 3 fold improvement of rescue of
F508del homozygous CFTR activity when compared with Lumacaftor/Ivacaftor treatment (van
Koningsbruggen-Rietschel et al., 2019). While the lung efficiency improvement in human trials
was only modest, it is important to note the patients were already receiving Lumacaftor/Ivacaftor
treatment (van Koningsbruggen-Rietschel et al., 2019). The addition of GLPG2737 further
improved their lung function. This fact warrants further research into GLPG2737 as an
Elexacaftor alternative. In addition, AbbVie/Galapagos recently completed a phase 1 study
combining GLPG 2222, GLPG 2737, and GLPG 2451 to test their own triple-combination drugs
(Clinical Trials, 2019). In the next few years, AbbVie/Galapagos may release either their own
triple combination therapy or novel drugs to increase the benefit of existing modulator therapies.
Flatley Discovery Lab and Proteostasis Therapeutics have both developed correctors and
potentiators than can be used in place of or in addition to various Vertex drugs. Both of these
companies recently completed phase 2 clinical trials with these drugs, but as of December 2019
have not published journal articles, so results of these trials are not reported here. In the next
couple of years, it is likely that another pharmaceutical company may be able to create a
competing modulator.
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Table 6: New Drug Research
NAME
Participants
Reference

Treatment

29

Percent
Change in
ppFEV1
50 mg: 1.1%
100 mg: .7%
200 mg: 1%
400 mg: 2.3%

(Bell et al.,
2019)

- F508del homo
- Age ≥ 18
- N=59

GLPG2222 50 mg, 100
mg, 200 mg, 400 mg,
QD
29 days

(Bell et al.,
2019)

- F508del + GM
- Age ≥ 18
- N=36

GLPG2222 150 mg,
150 mg: .2%
300 mg QD, + IVA 150 300 mg: 3%
mg BID
29 days

Sweat chloride
change
(mmol/L)
50 mg: -3.3
100 mg: - 4.1
200 mg: -15.8
400 mg: -6.3
150 mg: -10.4
300 mg: -11.6

PELICAN
- F508del homo
GLPG2737 75 mg BID 3.4%
-19.6
(van
- Age ≥ 18
+ LUM 400 mg + IVA
Koningsbrugg - N=22
250 mg BID
en-Rietschel
28 days
et al., 2019)
Note. All placebo controlled, phase 2 or phase 3 clinical trials testing new modulator drugs published
before Dec 2019 were found through a literature search and compiled. Relative results comparing
treatment and placebo are listed in the last two columns. Homo = homozygous; IVA = Ivacaftor;

LUM = Lumacaftor; GM = gating mutation.
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Furthermore, research is not isolated to correcting CFTR; in fact, Spyryx Bioscience, Inc.
has developed a ENaC modulator known as SPX-101 (Couroux et al., 2019). By promoting
channel internalization, SPX-101 regulates ENaC activity, which reduces Na+ absorption from
ASL (Couroux et al., 2019). This novel approach illustrates that much more research can still be
done in the development of modulators. While only in phase 1 testing, SPX-101 creates an
entirely new class of modulators that lessen the effects of CF in a completely novel method.
The process of developing a new modulator therapy is not easy. From intensive scanning
through thousands of molecules to find a potential modulator, to cell culture testing, to in vitro
models, to in vivo testing in animal models, there are a lot of steps before a therapy even reaches
human clinical trials. From there, phase 1 safety trials are performed with a small number of nonCF and CF volunteers. Phase 2 trials test the safety and efficiency of the drug at different doses
and are followed by a phase 3 trial where a larger group of CF patients take the drug for an
extended period of time. Ideally each of these trials is placebo controlled, so the results of the
drug can be easily evaluated. In short, the development of modulator therapy for CF is a time and
money intensive process but well worth the effort.
Conclusion
The research into modulators has produced several life changing drugs. As of the end of
2019, modulator therapy is available for 90% of the CF population, and clinical results show
outstanding improvements in lung function. This is a major accomplishment! But there is still
more work to be done. Modulators can be developed for all CF patients and be improved upon so
that they are more effective and have less side effects.
Modulators are a revolutionary therapy and will drastically change the clinical approach
to treating CF. Rather than facing continued failures as genetic therapy research has, modulators
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have been proven to cause clinical change without major adverse effects. Modulators are able to
significantly fix the root cause of CF by reestablishing CFTR function rather than only treating
symptoms as downstream therapies do. When combined with downstream therapies, modulators
can create a therapy regimen that prolongs and improves the life of CF patients.
CF modulator therapy has come a long way from when Ivacaftor was released in 2012,
yet there is still further modulator therapy can go. The second generation, triple combination
modulators were a significant improvement and opened the doors for more people to receive
effective modulator treatment. But researchers are nowhere close of finding the limits of
modulators. Trikafta uses two correctors and a potentiator, but there is another whole class of
modulators that needs to be explored more fully: amplifiers; as well as modulators that interact
with ENaC. CF research is just finding the tip of the iceberg of what can be done through
modulator therapy.
Modulators are the CF treatment of the future. The ultimate goal of CF research is to
improve and lengthen the lives of CF patients. Research into modulators have shown very
promising results including significant clinical benefit, increase lung efficiency, decreased
pulmonary exacerbations, and longer and healthier lives for people with CF. Modulator research
provides hope that one day a treatment or combination of treatments will allow CF patients to
live normal lives without worrying about the effects of what was once a chronic, progressive,
deadly disease. Modulators are the path to a brighter future for those with cystic fibrosis.
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